The vesamicol receptor ligand (+)-meta-[125i]iodobenzyltrozamicol {(+)-[125i]-mibt} reveals blunting of the striatal cholinergic response to dopamine d2 receptor blockade in the 6-hydroxydopamine (6-ohda)-lesioned rat: Possible implications for Parkinson's disease

Life Sciences

Volumn 58, Issue 16, 1996, Pages 1367-1374

  Efange, Simon M N ^a,b   Langason, Rosemary B ^b   Khare, Anil B ^b   Low, Walter C ^b  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

6 hydroxydopamine; Dopamine antagonists; Ligand binding; Vesamicol receptor

Indexed keywords

3 IODOBENZYLTROZAMICOL; ACETYLCHOLINESTERASE; DESIPRAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; IODINE 125; OXIDOPAMINE; PARGYLINE; SPIPERONE; UNCLASSIFIED DRUG; VESAMICOL DERIVATIVE; VESAMICOL RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ASYMMETRY; BRAIN CORTEX; BRAIN INJURY; CEREBELLUM; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DEPLETION; DOPAMINERGIC SYSTEM; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; LIGAND BINDING; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; RAT;

ANIMALS; BRAIN DISEASES; CHOLINERGIC FIBERS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE ANTAGONISTS; IODINE RADIOISOTOPES; IODOBENZENES; LIGANDS; MALE; OXIDOPAMINE; PARKINSON DISEASE; PIPERIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, CHOLINERGIC; RECEPTORS, DOPAMINE D2; SPIPERONE;

ANIMALIA;

EID: 0029964264     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/0024-3205(96)00103-8     Document Type: Article

References (26)

1. S.M. PARSONS, C. PRIOR and LG. MARSHALL, Intl. Rev. Neurobiol. 35 279-390 (1993).
2. T.B. USDIN, L.E. EIDEN, T.I. BONNER and J.D. ERICKSON, Trends Neurosci. 18 218-224 (1995).
3. S.M.N. EFANGE, A.B. KHARE, S.M. PARSONS, R. BAU and T. METZENTHIN, J. Med. Chem. 36 985-989 (1993).
4. S.M.N. EFANGE, A.B. KHARE, C. FOULON, S.K. AKELLA and S.M. PARSONS, J. Med. Chem. 37 2574-2582 (1994).
5. S.M.N. EFANGE, R.H. MICHELSON, A.B. KHARE and U.R. THOMAS, J. Med. Chem. 36 1754-1760 (1993).
6. S.M.N. EFANGE, R.H. MACH, A.B. KHARE, R.H. MICHELSON, P.A. NOWAK and P.H. EVORA, Appl. Radiat. Isot. 45 465-472 (1994).
7. M. INGVAR, S. STONE-ELANDER, G.A. ROGERS, B. JOHANSSON, L. ERIKSSON, S.M. PARSONS and L. WIDEN, Neuroreport 4 1311-1314 (1993).
8. J.C. STOOF, B. DRUKARCH, P. DE BOER, B.H.C. WESTERINK and H.J. GROENEWEGEN, Neurosci. 47 755-770 (1992).
9. S.P. CONSOLO, P. GIROTTI, M. ZAMBELLI, G. RUSSI, M. BENZI and BERTORELLI, Progr. Neurobiol. 98 201-207 (1993).
10. G. RUSSI, P. GIROTTI, C. CADONI, G. DI CHIARA and S. CONSOLO, NeuroReport 4 1335-1338 (1993).
11. U. UNGERSTEDT, Eur. J. Pharmacol. 5 107-110 (1968).
12. U. UNGERSTEDT, Acta Physiol. Scand. 82 (suppl. 367) 69-93 (1971).
13. G. PAXINOS and C. WATSON. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1982.
14. D. FAGE, B. GUERIN, C. FEUERSTEIN, P. DEMENGE and B. SCATTON, Brain Res. 310 379-383 (1984).
15. J. KORF and J.B. SEBENS, J. Neurochem. 48 516-521 (1987).
16. R.G. MACKENZIE, M.K. STACHOWIAK and M.J. ZIGMOND, Eur. J. Pharmacol. 168 43-52 (1989).
17. J. GLOWINSKI and L.L. IVERSEN, J. Neurochem. 13 655-669 (1966).
18. P.R. LEWIS and C.C.D. SHUTE, Brain 90 497-520 (1967).
19. R. KUCZENSKI, D.S. SEGAL and A.J. MANDELL, J. Neurochem. 24 39-45 (1975).
20. W.B. STAVINOHA, S.T. WEINTRAUB and A.T. MODAK, J. Neurochem. 23 885-886 (1974).
21. R. QUIRION, Synapse 1 293-303 (1987).
22. I.J. KOPIN, Neuropharmacology 9 1-12 (1993).
23. A. ENZ, M. GOLDSTEIN and E. MELLER, Molec. Pharmacol. 37 560-565 (1990).
24. R.K. CARDER, D JACKSON, H.J. MORRIS, R.D. LUND and M.J. ZIGMOND, Exptl. Neurol. 105 251-259 (1989).
25. H. ROMMELSPACHER and M.J. KUHAR, Life Sci. 16 65-70 (1975).
26. S.M.N. EFANGE, R.B. LANGASON and A.B. KHARE, J. Nucl. Med., in press.